nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—Nucleoside Analog—Azathioprine—multiple sclerosis	0.556	1	CiPCiCtD
Valganciclovir—SLC15A2—multiple sclerosis	0.36	1	CbGaD
Valganciclovir—SLC15A1—Proton/oligonucleotide cotransporters—SLC15A2—multiple sclerosis	0.00365	0.392	CbGpPWpGaD
Valganciclovir—Valaciclovir—SLC15A2—multiple sclerosis	0.00147	1	CrCbGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC15A2—multiple sclerosis	0.00112	0.12	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC15A2—multiple sclerosis	0.000659	0.0709	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC15A2—multiple sclerosis	0.000491	0.0529	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000491	0.0528	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000343	0.0369	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000294	0.0317	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC15A2—multiple sclerosis	0.000289	0.0311	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000223	0.024	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000156	0.0168	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00015	0.0161	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000135	0.0146	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000129	0.0139	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000113	0.0122	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000106	0.0114	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	9.79e-05	0.0105	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.96e-05	0.00964	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.92e-05	0.00853	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	7.37e-05	0.00794	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	6.84e-05	0.00736	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	6.57e-05	0.00707	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—TGFB1—multiple sclerosis	5.63e-05	0.00606	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—ALB—multiple sclerosis	5.61e-05	0.00604	CbGpPWpGaD
Valganciclovir—Confusional state—Methylprednisolone—multiple sclerosis	5.57e-05	0.000761	CcSEcCtD
Valganciclovir—Immune system disorder—Prednisone—multiple sclerosis	5.56e-05	0.00076	CcSEcCtD
Valganciclovir—Malaise—Dexamethasone—multiple sclerosis	5.55e-05	0.000758	CcSEcCtD
Valganciclovir—Malaise—Betamethasone—multiple sclerosis	5.55e-05	0.000758	CcSEcCtD
Valganciclovir—Oedema—Triamcinolone—multiple sclerosis	5.53e-05	0.000756	CcSEcCtD
Valganciclovir—Anaphylactic shock—Triamcinolone—multiple sclerosis	5.53e-05	0.000756	CcSEcCtD
Valganciclovir—Vertigo—Dexamethasone—multiple sclerosis	5.53e-05	0.000756	CcSEcCtD
Valganciclovir—Vertigo—Betamethasone—multiple sclerosis	5.53e-05	0.000756	CcSEcCtD
Valganciclovir—Anaphylactic shock—Methylprednisolone—multiple sclerosis	5.52e-05	0.000755	CcSEcCtD
Valganciclovir—Arrhythmia—Prednisone—multiple sclerosis	5.5e-05	0.000752	CcSEcCtD
Valganciclovir—Infection—Triamcinolone—multiple sclerosis	5.5e-05	0.000752	CcSEcCtD
Valganciclovir—Infection—Methylprednisolone—multiple sclerosis	5.49e-05	0.00075	CcSEcCtD
Valganciclovir—Haematuria—Methotrexate—multiple sclerosis	5.46e-05	0.000747	CcSEcCtD
Valganciclovir—Insomnia—Prednisolone—multiple sclerosis	5.44e-05	0.000744	CcSEcCtD
Valganciclovir—Alopecia—Prednisone—multiple sclerosis	5.44e-05	0.000744	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Methotrexate—multiple sclerosis	5.42e-05	0.000741	CcSEcCtD
Valganciclovir—Nervous system disorder—Methylprednisolone—multiple sclerosis	5.41e-05	0.00074	CcSEcCtD
Valganciclovir—Hypersensitivity—Mitoxantrone—multiple sclerosis	5.4e-05	0.000739	CcSEcCtD
Valganciclovir—Paraesthesia—Prednisolone—multiple sclerosis	5.4e-05	0.000739	CcSEcCtD
Valganciclovir—Tachycardia—Triamcinolone—multiple sclerosis	5.4e-05	0.000738	CcSEcCtD
Valganciclovir—Mental disorder—Prednisone—multiple sclerosis	5.39e-05	0.000737	CcSEcCtD
Valganciclovir—Nausea—Azathioprine—multiple sclerosis	5.39e-05	0.000737	CcSEcCtD
Valganciclovir—Tachycardia—Methylprednisolone—multiple sclerosis	5.39e-05	0.000737	CcSEcCtD
Valganciclovir—Skin disorder—Methylprednisolone—multiple sclerosis	5.36e-05	0.000733	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.36e-05	0.00577	CbGpPWpGaD
Valganciclovir—Malnutrition—Prednisone—multiple sclerosis	5.36e-05	0.000732	CcSEcCtD
Valganciclovir—Hyperhidrosis—Triamcinolone—multiple sclerosis	5.35e-05	0.000731	CcSEcCtD
Valganciclovir—Hyperhidrosis—Methylprednisolone—multiple sclerosis	5.34e-05	0.00073	CcSEcCtD
Valganciclovir—Convulsion—Dexamethasone—multiple sclerosis	5.33e-05	0.000729	CcSEcCtD
Valganciclovir—Convulsion—Betamethasone—multiple sclerosis	5.33e-05	0.000729	CcSEcCtD
Valganciclovir—Hypertension—Betamethasone—multiple sclerosis	5.31e-05	0.000726	CcSEcCtD
Valganciclovir—Hypertension—Dexamethasone—multiple sclerosis	5.31e-05	0.000726	CcSEcCtD
Valganciclovir—Asthenia—Mitoxantrone—multiple sclerosis	5.26e-05	0.000719	CcSEcCtD
Valganciclovir—Anxiety—Dexamethasone—multiple sclerosis	5.22e-05	0.000714	CcSEcCtD
Valganciclovir—Anxiety—Betamethasone—multiple sclerosis	5.22e-05	0.000714	CcSEcCtD
Valganciclovir—Discomfort—Betamethasone—multiple sclerosis	5.18e-05	0.000707	CcSEcCtD
Valganciclovir—Discomfort—Dexamethasone—multiple sclerosis	5.18e-05	0.000707	CcSEcCtD
Valganciclovir—Haemoglobin—Methotrexate—multiple sclerosis	5.17e-05	0.000707	CcSEcCtD
Valganciclovir—Hypotension—Methylprednisolone—multiple sclerosis	5.16e-05	0.000705	CcSEcCtD
Valganciclovir—Pain—Prednisolone—multiple sclerosis	5.15e-05	0.000703	CcSEcCtD
Valganciclovir—Haemorrhage—Methotrexate—multiple sclerosis	5.14e-05	0.000703	CcSEcCtD
Valganciclovir—Hepatitis—Methotrexate—multiple sclerosis	5.14e-05	0.000703	CcSEcCtD
Valganciclovir—Pharyngitis—Methotrexate—multiple sclerosis	5.11e-05	0.000698	CcSEcCtD
Valganciclovir—Urinary tract disorder—Methotrexate—multiple sclerosis	5.08e-05	0.000694	CcSEcCtD
Valganciclovir—Vision blurred—Prednisone—multiple sclerosis	5.05e-05	0.00069	CcSEcCtD
Valganciclovir—Urethral disorder—Methotrexate—multiple sclerosis	5.04e-05	0.000689	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.04e-05	0.000689	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.03e-05	0.000688	CcSEcCtD
Valganciclovir—Oedema—Dexamethasone—multiple sclerosis	5.02e-05	0.000686	CcSEcCtD
Valganciclovir—Oedema—Betamethasone—multiple sclerosis	5.02e-05	0.000686	CcSEcCtD
Valganciclovir—Anaphylactic shock—Dexamethasone—multiple sclerosis	5.02e-05	0.000686	CcSEcCtD
Valganciclovir—Anaphylactic shock—Betamethasone—multiple sclerosis	5.02e-05	0.000686	CcSEcCtD
Valganciclovir—Diarrhoea—Mitoxantrone—multiple sclerosis	5.02e-05	0.000686	CcSEcCtD
Valganciclovir—Insomnia—Triamcinolone—multiple sclerosis	5.01e-05	0.000684	CcSEcCtD
Valganciclovir—Insomnia—Methylprednisolone—multiple sclerosis	4.99e-05	0.000683	CcSEcCtD
Valganciclovir—Infection—Betamethasone—multiple sclerosis	4.99e-05	0.000682	CcSEcCtD
Valganciclovir—Infection—Dexamethasone—multiple sclerosis	4.99e-05	0.000682	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.98e-05	0.00536	CbGpPWpGaD
Valganciclovir—Ill-defined disorder—Prednisone—multiple sclerosis	4.97e-05	0.00068	CcSEcCtD
Valganciclovir—Paraesthesia—Triamcinolone—multiple sclerosis	4.97e-05	0.000679	CcSEcCtD
Valganciclovir—Feeling abnormal—Prednisolone—multiple sclerosis	4.96e-05	0.000678	CcSEcCtD
Valganciclovir—Paraesthesia—Methylprednisolone—multiple sclerosis	4.96e-05	0.000678	CcSEcCtD
Valganciclovir—Visual impairment—Methotrexate—multiple sclerosis	4.96e-05	0.000678	CcSEcCtD
Valganciclovir—Anaemia—Prednisone—multiple sclerosis	4.95e-05	0.000677	CcSEcCtD
Valganciclovir—Dyspnoea—Triamcinolone—multiple sclerosis	4.93e-05	0.000674	CcSEcCtD
Valganciclovir—Nervous system disorder—Betamethasone—multiple sclerosis	4.92e-05	0.000673	CcSEcCtD
Valganciclovir—Nervous system disorder—Dexamethasone—multiple sclerosis	4.92e-05	0.000673	CcSEcCtD
Valganciclovir—Agitation—Prednisone—multiple sclerosis	4.92e-05	0.000673	CcSEcCtD
Valganciclovir—Thrombocytopenia—Dexamethasone—multiple sclerosis	4.92e-05	0.000672	CcSEcCtD
Valganciclovir—Thrombocytopenia—Betamethasone—multiple sclerosis	4.92e-05	0.000672	CcSEcCtD
Valganciclovir—Tachycardia—Dexamethasone—multiple sclerosis	4.9e-05	0.00067	CcSEcCtD
Valganciclovir—Tachycardia—Betamethasone—multiple sclerosis	4.9e-05	0.00067	CcSEcCtD
Valganciclovir—Dyspepsia—Triamcinolone—multiple sclerosis	4.87e-05	0.000666	CcSEcCtD
Valganciclovir—Dyspepsia—Methylprednisolone—multiple sclerosis	4.86e-05	0.000664	CcSEcCtD
Valganciclovir—Hyperhidrosis—Dexamethasone—multiple sclerosis	4.85e-05	0.000664	CcSEcCtD
Valganciclovir—Hyperhidrosis—Betamethasone—multiple sclerosis	4.85e-05	0.000664	CcSEcCtD
Valganciclovir—Malaise—Prednisone—multiple sclerosis	4.83e-05	0.000661	CcSEcCtD
Valganciclovir—Vertigo—Prednisone—multiple sclerosis	4.81e-05	0.000658	CcSEcCtD
Valganciclovir—Eye disorder—Methotrexate—multiple sclerosis	4.81e-05	0.000657	CcSEcCtD
Valganciclovir—Tinnitus—Methotrexate—multiple sclerosis	4.8e-05	0.000656	CcSEcCtD
Valganciclovir—Anorexia—Dexamethasone—multiple sclerosis	4.79e-05	0.000654	CcSEcCtD
Valganciclovir—Anorexia—Betamethasone—multiple sclerosis	4.79e-05	0.000654	CcSEcCtD
Valganciclovir—Urticaria—Prednisolone—multiple sclerosis	4.78e-05	0.000654	CcSEcCtD
Valganciclovir—Cardiac disorder—Methotrexate—multiple sclerosis	4.77e-05	0.000653	CcSEcCtD
Valganciclovir—Fatigue—Triamcinolone—multiple sclerosis	4.77e-05	0.000652	CcSEcCtD
Valganciclovir—Fatigue—Methylprednisolone—multiple sclerosis	4.76e-05	0.000651	CcSEcCtD
Valganciclovir—Pain—Triamcinolone—multiple sclerosis	4.73e-05	0.000647	CcSEcCtD
Valganciclovir—Hypotension—Betamethasone—multiple sclerosis	4.69e-05	0.000641	CcSEcCtD
Valganciclovir—Hypotension—Dexamethasone—multiple sclerosis	4.69e-05	0.000641	CcSEcCtD
Valganciclovir—Angiopathy—Methotrexate—multiple sclerosis	4.67e-05	0.000638	CcSEcCtD
Valganciclovir—Vomiting—Mitoxantrone—multiple sclerosis	4.66e-05	0.000638	CcSEcCtD
Valganciclovir—Immune system disorder—Methotrexate—multiple sclerosis	4.65e-05	0.000635	CcSEcCtD
Valganciclovir—Convulsion—Prednisone—multiple sclerosis	4.64e-05	0.000635	CcSEcCtD
Valganciclovir—Mediastinal disorder—Methotrexate—multiple sclerosis	4.64e-05	0.000634	CcSEcCtD
Valganciclovir—Hypertension—Prednisone—multiple sclerosis	4.63e-05	0.000632	CcSEcCtD
Valganciclovir—Dermatitis—Mitoxantrone—multiple sclerosis	4.62e-05	0.000632	CcSEcCtD
Valganciclovir—Chills—Methotrexate—multiple sclerosis	4.62e-05	0.000631	CcSEcCtD
Valganciclovir—Headache—Mitoxantrone—multiple sclerosis	4.6e-05	0.000628	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.57e-05	0.000625	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.57e-05	0.000625	CcSEcCtD
Valganciclovir—Arthralgia—Prednisone—multiple sclerosis	4.56e-05	0.000624	CcSEcCtD
Valganciclovir—Feeling abnormal—Triamcinolone—multiple sclerosis	4.56e-05	0.000623	CcSEcCtD
Valganciclovir—Feeling abnormal—Methylprednisolone—multiple sclerosis	4.55e-05	0.000622	CcSEcCtD
Valganciclovir—Anxiety—Prednisone—multiple sclerosis	4.55e-05	0.000621	CcSEcCtD
Valganciclovir—Alopecia—Methotrexate—multiple sclerosis	4.55e-05	0.000621	CcSEcCtD
Valganciclovir—Insomnia—Dexamethasone—multiple sclerosis	4.54e-05	0.000621	CcSEcCtD
Valganciclovir—Insomnia—Betamethasone—multiple sclerosis	4.54e-05	0.000621	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.53e-05	0.000619	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.52e-05	0.000617	CcSEcCtD
Valganciclovir—Paraesthesia—Dexamethasone—multiple sclerosis	4.51e-05	0.000616	CcSEcCtD
Valganciclovir—Paraesthesia—Betamethasone—multiple sclerosis	4.51e-05	0.000616	CcSEcCtD
Valganciclovir—Discomfort—Prednisone—multiple sclerosis	4.51e-05	0.000616	CcSEcCtD
Valganciclovir—Mental disorder—Methotrexate—multiple sclerosis	4.51e-05	0.000616	CcSEcCtD
Valganciclovir—Malnutrition—Methotrexate—multiple sclerosis	4.48e-05	0.000612	CcSEcCtD
Valganciclovir—Hypersensitivity—Prednisolone—multiple sclerosis	4.43e-05	0.000606	CcSEcCtD
Valganciclovir—Dyspepsia—Dexamethasone—multiple sclerosis	4.42e-05	0.000604	CcSEcCtD
Valganciclovir—Dyspepsia—Betamethasone—multiple sclerosis	4.42e-05	0.000604	CcSEcCtD
Valganciclovir—Urticaria—Triamcinolone—multiple sclerosis	4.4e-05	0.000601	CcSEcCtD
Valganciclovir—Urticaria—Methylprednisolone—multiple sclerosis	4.39e-05	0.0006	CcSEcCtD
Valganciclovir—Dysgeusia—Methotrexate—multiple sclerosis	4.39e-05	0.000599	CcSEcCtD
Valganciclovir—Body temperature increased—Triamcinolone—multiple sclerosis	4.37e-05	0.000598	CcSEcCtD
Valganciclovir—Anaphylactic shock—Prednisone—multiple sclerosis	4.37e-05	0.000598	CcSEcCtD
Valganciclovir—Oedema—Prednisone—multiple sclerosis	4.37e-05	0.000598	CcSEcCtD
Valganciclovir—Abdominal pain—Methylprednisolone—multiple sclerosis	4.36e-05	0.000597	CcSEcCtD
Valganciclovir—Decreased appetite—Dexamethasone—multiple sclerosis	4.36e-05	0.000597	CcSEcCtD
Valganciclovir—Decreased appetite—Betamethasone—multiple sclerosis	4.36e-05	0.000597	CcSEcCtD
Valganciclovir—Nausea—Mitoxantrone—multiple sclerosis	4.36e-05	0.000596	CcSEcCtD
Valganciclovir—Infection—Prednisone—multiple sclerosis	4.34e-05	0.000594	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.34e-05	0.000593	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.34e-05	0.000593	CcSEcCtD
Valganciclovir—Back pain—Methotrexate—multiple sclerosis	4.33e-05	0.000592	CcSEcCtD
Valganciclovir—Fatigue—Dexamethasone—multiple sclerosis	4.33e-05	0.000592	CcSEcCtD
Valganciclovir—Fatigue—Betamethasone—multiple sclerosis	4.33e-05	0.000592	CcSEcCtD
Valganciclovir—Pain—Dexamethasone—multiple sclerosis	4.29e-05	0.000587	CcSEcCtD
Valganciclovir—Pain—Betamethasone—multiple sclerosis	4.29e-05	0.000587	CcSEcCtD
Valganciclovir—Nervous system disorder—Prednisone—multiple sclerosis	4.29e-05	0.000586	CcSEcCtD
Valganciclovir—Tachycardia—Prednisone—multiple sclerosis	4.27e-05	0.000583	CcSEcCtD
Valganciclovir—Skin disorder—Prednisone—multiple sclerosis	4.25e-05	0.000581	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.24e-05	0.00456	CbGpPWpGaD
Valganciclovir—Hyperhidrosis—Prednisone—multiple sclerosis	4.23e-05	0.000578	CcSEcCtD
Valganciclovir—Vision blurred—Methotrexate—multiple sclerosis	4.22e-05	0.000577	CcSEcCtD
Valganciclovir—Anorexia—Prednisone—multiple sclerosis	4.17e-05	0.00057	CcSEcCtD
Valganciclovir—Ill-defined disorder—Methotrexate—multiple sclerosis	4.15e-05	0.000568	CcSEcCtD
Valganciclovir—Anaemia—Methotrexate—multiple sclerosis	4.14e-05	0.000566	CcSEcCtD
Valganciclovir—Feeling abnormal—Betamethasone—multiple sclerosis	4.14e-05	0.000566	CcSEcCtD
Valganciclovir—Feeling abnormal—Dexamethasone—multiple sclerosis	4.14e-05	0.000566	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.11e-05	0.000561	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.11e-05	0.000561	CcSEcCtD
Valganciclovir—Hypersensitivity—Triamcinolone—multiple sclerosis	4.08e-05	0.000557	CcSEcCtD
Valganciclovir—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.07e-05	0.000556	CcSEcCtD
Valganciclovir—Malaise—Methotrexate—multiple sclerosis	4.04e-05	0.000552	CcSEcCtD
Valganciclovir—Vertigo—Methotrexate—multiple sclerosis	4.02e-05	0.00055	CcSEcCtD
Valganciclovir—Leukopenia—Methotrexate—multiple sclerosis	4.01e-05	0.000548	CcSEcCtD
Valganciclovir—Urticaria—Betamethasone—multiple sclerosis	3.99e-05	0.000545	CcSEcCtD
Valganciclovir—Urticaria—Dexamethasone—multiple sclerosis	3.99e-05	0.000545	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Prednisone—multiple sclerosis	3.98e-05	0.000545	CcSEcCtD
Valganciclovir—Dizziness—Prednisolone—multiple sclerosis	3.98e-05	0.000544	CcSEcCtD
Valganciclovir—Asthenia—Triamcinolone—multiple sclerosis	3.97e-05	0.000543	CcSEcCtD
Valganciclovir—Abdominal pain—Betamethasone—multiple sclerosis	3.97e-05	0.000543	CcSEcCtD
Valganciclovir—Body temperature increased—Dexamethasone—multiple sclerosis	3.97e-05	0.000543	CcSEcCtD
Valganciclovir—Body temperature increased—Betamethasone—multiple sclerosis	3.97e-05	0.000543	CcSEcCtD
Valganciclovir—Abdominal pain—Dexamethasone—multiple sclerosis	3.97e-05	0.000543	CcSEcCtD
Valganciclovir—Asthenia—Methylprednisolone—multiple sclerosis	3.96e-05	0.000542	CcSEcCtD
Valganciclovir—Insomnia—Prednisone—multiple sclerosis	3.96e-05	0.000541	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.93e-05	0.00423	CbGpPWpGaD
Valganciclovir—Paraesthesia—Prednisone—multiple sclerosis	3.93e-05	0.000537	CcSEcCtD
Valganciclovir—Pruritus—Triamcinolone—multiple sclerosis	3.92e-05	0.000535	CcSEcCtD
Valganciclovir—Cough—Methotrexate—multiple sclerosis	3.91e-05	0.000534	CcSEcCtD
Valganciclovir—Pruritus—Methylprednisolone—multiple sclerosis	3.91e-05	0.000534	CcSEcCtD
Valganciclovir—Convulsion—Methotrexate—multiple sclerosis	3.88e-05	0.00053	CcSEcCtD
Valganciclovir—Dyspepsia—Prednisone—multiple sclerosis	3.85e-05	0.000526	CcSEcCtD
Valganciclovir—Arthralgia—Methotrexate—multiple sclerosis	3.81e-05	0.000521	CcSEcCtD
Valganciclovir—Decreased appetite—Prednisone—multiple sclerosis	3.8e-05	0.00052	CcSEcCtD
Valganciclovir—Dermatitis—Prednisolone—multiple sclerosis	3.79e-05	0.000518	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.79e-05	0.000518	CcSEcCtD
Valganciclovir—Diarrhoea—Methylprednisolone—multiple sclerosis	3.78e-05	0.000516	CcSEcCtD
Valganciclovir—Fatigue—Prednisone—multiple sclerosis	3.77e-05	0.000515	CcSEcCtD
Valganciclovir—Headache—Prednisolone—multiple sclerosis	3.77e-05	0.000515	CcSEcCtD
Valganciclovir—Discomfort—Methotrexate—multiple sclerosis	3.77e-05	0.000515	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.75e-05	0.00403	CbGpPWpGaD
Valganciclovir—Constipation—Prednisone—multiple sclerosis	3.74e-05	0.000511	CcSEcCtD
Valganciclovir—Confusional state—Methotrexate—multiple sclerosis	3.68e-05	0.000504	CcSEcCtD
Valganciclovir—Dizziness—Triamcinolone—multiple sclerosis	3.66e-05	0.0005	CcSEcCtD
Valganciclovir—Anaphylactic shock—Methotrexate—multiple sclerosis	3.65e-05	0.0005	CcSEcCtD
Valganciclovir—Dizziness—Methylprednisolone—multiple sclerosis	3.65e-05	0.000499	CcSEcCtD
Valganciclovir—Infection—Methotrexate—multiple sclerosis	3.63e-05	0.000496	CcSEcCtD
Valganciclovir—Feeling abnormal—Prednisone—multiple sclerosis	3.6e-05	0.000493	CcSEcCtD
Valganciclovir—Asthenia—Betamethasone—multiple sclerosis	3.6e-05	0.000492	CcSEcCtD
Valganciclovir—Asthenia—Dexamethasone—multiple sclerosis	3.6e-05	0.000492	CcSEcCtD
Valganciclovir—Nervous system disorder—Methotrexate—multiple sclerosis	3.58e-05	0.00049	CcSEcCtD
Valganciclovir—Thrombocytopenia—Methotrexate—multiple sclerosis	3.58e-05	0.000489	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Prednisone—multiple sclerosis	3.58e-05	0.000489	CcSEcCtD
Valganciclovir—Nausea—Prednisolone—multiple sclerosis	3.57e-05	0.000489	CcSEcCtD
Valganciclovir—Pruritus—Betamethasone—multiple sclerosis	3.55e-05	0.000486	CcSEcCtD
Valganciclovir—Pruritus—Dexamethasone—multiple sclerosis	3.55e-05	0.000486	CcSEcCtD
Valganciclovir—Skin disorder—Methotrexate—multiple sclerosis	3.55e-05	0.000485	CcSEcCtD
Valganciclovir—Hyperhidrosis—Methotrexate—multiple sclerosis	3.53e-05	0.000483	CcSEcCtD
Valganciclovir—Vomiting—Triamcinolone—multiple sclerosis	3.52e-05	0.000481	CcSEcCtD
Valganciclovir—Vomiting—Methylprednisolone—multiple sclerosis	3.51e-05	0.00048	CcSEcCtD
Valganciclovir—Dermatitis—Triamcinolone—multiple sclerosis	3.49e-05	0.000477	CcSEcCtD
Valganciclovir—Anorexia—Methotrexate—multiple sclerosis	3.48e-05	0.000476	CcSEcCtD
Valganciclovir—Dermatitis—Methylprednisolone—multiple sclerosis	3.48e-05	0.000475	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.48e-05	0.00374	CbGpPWpGaD
Valganciclovir—Urticaria—Prednisone—multiple sclerosis	3.47e-05	0.000475	CcSEcCtD
Valganciclovir—Headache—Triamcinolone—multiple sclerosis	3.47e-05	0.000474	CcSEcCtD
Valganciclovir—Headache—Methylprednisolone—multiple sclerosis	3.46e-05	0.000473	CcSEcCtD
Valganciclovir—Abdominal pain—Prednisone—multiple sclerosis	3.46e-05	0.000473	CcSEcCtD
Valganciclovir—Body temperature increased—Prednisone—multiple sclerosis	3.46e-05	0.000473	CcSEcCtD
Valganciclovir—Diarrhoea—Betamethasone—multiple sclerosis	3.44e-05	0.00047	CcSEcCtD
Valganciclovir—Diarrhoea—Dexamethasone—multiple sclerosis	3.44e-05	0.00047	CcSEcCtD
Valganciclovir—Hypotension—Methotrexate—multiple sclerosis	3.41e-05	0.000467	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.33e-05	0.000455	CcSEcCtD
Valganciclovir—Dizziness—Dexamethasone—multiple sclerosis	3.32e-05	0.000454	CcSEcCtD
Valganciclovir—Dizziness—Betamethasone—multiple sclerosis	3.32e-05	0.000454	CcSEcCtD
Valganciclovir—Insomnia—Methotrexate—multiple sclerosis	3.31e-05	0.000452	CcSEcCtD
Valganciclovir—Nausea—Triamcinolone—multiple sclerosis	3.29e-05	0.000449	CcSEcCtD
Valganciclovir—Paraesthesia—Methotrexate—multiple sclerosis	3.28e-05	0.000449	CcSEcCtD
Valganciclovir—Nausea—Methylprednisolone—multiple sclerosis	3.28e-05	0.000448	CcSEcCtD
Valganciclovir—Dyspnoea—Methotrexate—multiple sclerosis	3.26e-05	0.000445	CcSEcCtD
Valganciclovir—Somnolence—Methotrexate—multiple sclerosis	3.25e-05	0.000444	CcSEcCtD
Valganciclovir—Hypersensitivity—Prednisone—multiple sclerosis	3.22e-05	0.00044	CcSEcCtD
Valganciclovir—Dyspepsia—Methotrexate—multiple sclerosis	3.22e-05	0.00044	CcSEcCtD
Valganciclovir—Vomiting—Dexamethasone—multiple sclerosis	3.19e-05	0.000436	CcSEcCtD
Valganciclovir—Vomiting—Betamethasone—multiple sclerosis	3.19e-05	0.000436	CcSEcCtD
Valganciclovir—Decreased appetite—Methotrexate—multiple sclerosis	3.18e-05	0.000434	CcSEcCtD
Valganciclovir—Dermatitis—Betamethasone—multiple sclerosis	3.16e-05	0.000432	CcSEcCtD
Valganciclovir—Dermatitis—Dexamethasone—multiple sclerosis	3.16e-05	0.000432	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.16e-05	0.000431	CcSEcCtD
Valganciclovir—Fatigue—Methotrexate—multiple sclerosis	3.15e-05	0.000431	CcSEcCtD
Valganciclovir—Headache—Betamethasone—multiple sclerosis	3.15e-05	0.00043	CcSEcCtD
Valganciclovir—Headache—Dexamethasone—multiple sclerosis	3.15e-05	0.00043	CcSEcCtD
Valganciclovir—Asthenia—Prednisone—multiple sclerosis	3.14e-05	0.000429	CcSEcCtD
Valganciclovir—Pain—Methotrexate—multiple sclerosis	3.13e-05	0.000427	CcSEcCtD
Valganciclovir—Pruritus—Prednisone—multiple sclerosis	3.09e-05	0.000423	CcSEcCtD
Valganciclovir—Feeling abnormal—Methotrexate—multiple sclerosis	3.01e-05	0.000412	CcSEcCtD
Valganciclovir—Diarrhoea—Prednisone—multiple sclerosis	2.99e-05	0.000409	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.99e-05	0.000409	CcSEcCtD
Valganciclovir—Nausea—Dexamethasone—multiple sclerosis	2.98e-05	0.000408	CcSEcCtD
Valganciclovir—Nausea—Betamethasone—multiple sclerosis	2.98e-05	0.000408	CcSEcCtD
Valganciclovir—Urticaria—Methotrexate—multiple sclerosis	2.9e-05	0.000397	CcSEcCtD
Valganciclovir—Dizziness—Prednisone—multiple sclerosis	2.89e-05	0.000395	CcSEcCtD
Valganciclovir—Abdominal pain—Methotrexate—multiple sclerosis	2.89e-05	0.000395	CcSEcCtD
Valganciclovir—Body temperature increased—Methotrexate—multiple sclerosis	2.89e-05	0.000395	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.85e-05	0.00307	CbGpPWpGaD
Valganciclovir—Vomiting—Prednisone—multiple sclerosis	2.78e-05	0.00038	CcSEcCtD
Valganciclovir—Dermatitis—Prednisone—multiple sclerosis	2.75e-05	0.000377	CcSEcCtD
Valganciclovir—Headache—Prednisone—multiple sclerosis	2.74e-05	0.000374	CcSEcCtD
Valganciclovir—Hypersensitivity—Methotrexate—multiple sclerosis	2.69e-05	0.000368	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.66e-05	0.00286	CbGpPWpGaD
Valganciclovir—Asthenia—Methotrexate—multiple sclerosis	2.62e-05	0.000358	CcSEcCtD
Valganciclovir—Nausea—Prednisone—multiple sclerosis	2.6e-05	0.000355	CcSEcCtD
Valganciclovir—Pruritus—Methotrexate—multiple sclerosis	2.59e-05	0.000353	CcSEcCtD
Valganciclovir—Diarrhoea—Methotrexate—multiple sclerosis	2.5e-05	0.000342	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.46e-05	0.00265	CbGpPWpGaD
Valganciclovir—Dizziness—Methotrexate—multiple sclerosis	2.42e-05	0.00033	CcSEcCtD
Valganciclovir—Vomiting—Methotrexate—multiple sclerosis	2.32e-05	0.000318	CcSEcCtD
Valganciclovir—Dermatitis—Methotrexate—multiple sclerosis	2.3e-05	0.000315	CcSEcCtD
Valganciclovir—Headache—Methotrexate—multiple sclerosis	2.29e-05	0.000313	CcSEcCtD
Valganciclovir—Nausea—Methotrexate—multiple sclerosis	2.17e-05	0.000297	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.35e-05	0.00145	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.25e-05	0.00135	CbGpPWpGaD
